Related Experiment Videos
[Efficacy of adenosine triphosphate in terminating supraventricular tachycardia]
J Schläpfer1, M Fromer, L Kappenberger
1Division de cardiologie, CHUV, Lausanne.
Abstract:
The efficacy of adenosine triphosphate (ATP) was tested in 23 patients suffering from supraventricular tachycardia; 10 patients had orthodromic circus movement tachycardia and 13 typical av nodal reentrant tachycardia. At a mean dose of 0.18 mg/kg all tachycardias were halted in less than 1 minute due to transient acute av nodal block followed by return to normal av conduction within 8 seconds. All patients had transient minor side effects. One elderly subject had a short episode of atrial fibrillation after the acute av block. In conclusion, ATP is useful and safe for rapid termination of supraventricular tachycardias incorporating the av node in their circuit.
Insights
Adenosine triphosphate (ATP) effectively and safely terminates supraventricular tachycardia in patients by causing a brief atrioventricular nodal block. This rapid treatment is useful for tachycardias involving the AV node.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Context:
- Supraventricular tachycardia (SVT) is a common arrhythmia.
- Current treatments for SVT can be invasive or have significant side effects.
- Adenosine triphosphate (ATP) is a potential therapeutic agent for SVT.
Purpose:
- To evaluate the efficacy and safety of adenosine triphosphate (ATP) in terminating supraventricular tachycardia (SVT).
Summary:
- Adenosine triphosphate (ATP) was administered to 23 patients with supraventricular tachycardia (SVT), including orthodromic circus movement tachycardia and typical AV nodal reentrant tachycardia.
- A mean dose of 0.18 mg/kg rapidly halted all tachycardias within 1 minute via transient acute AV nodal block.
- Normal AV conduction returned within 8 seconds, with all patients experiencing minor, transient side effects. One elderly patient had a brief episode of atrial fibrillation.
Impact:
- Adenosine triphosphate (ATP) is a safe and effective option for the rapid termination of supraventricular tachycardias (SVT) that involve the atrioventricular (AV) node.
- This study supports the use of ATP as a first-line treatment for specific types of SVT.
- Further research may explore optimal dosing and long-term effects in diverse patient populations.